Regeneron Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Regeneron Pharmaceuticals has been growing earnings at an average annual rate of 7.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 12.8% per year. Regeneron Pharmaceuticals's return on equity is 15.9%, and it has net margins of 33.6%.
Key information
7.3%
Earnings growth rate
7.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 12.8% |
| Return on equity | 15.9% |
| Net Margin | 33.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Regeneron: The Biotech Stock To Buy Now
Nov 19Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Nov 04Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sep 25Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Sep 09
Regeneron Stock: Valuation Now Demands More Growth
Aug 26Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Revenue & Expenses Breakdown
How Regeneron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 13,847 | 4,655 | 2,900 | 0 |
| 30 Jun 24 | 13,489 | 4,322 | 2,826 | 265 |
| 31 Mar 24 | 13,100 | 3,858 | 2,719 | 0 |
| 31 Dec 23 | 13,117 | 3,954 | 2,631 | 0 |
| 30 Sep 23 | 13,097 | 3,991 | 2,554 | 0 |
| 30 Jun 23 | 12,671 | 4,299 | 2,443 | 1,938 |
| 31 Mar 23 | 12,370 | 4,183 | 2,267 | 0 |
| 31 Dec 22 | 12,173 | 4,338 | 2,116 | 0 |
| 30 Sep 22 | 13,710 | 5,370 | 2,015 | 0 |
| 30 Jun 22 | 14,227 | 5,687 | 1,931 | 0 |
| 31 Mar 22 | 16,508 | 7,934 | 1,869 | 0 |
| 31 Dec 21 | 16,072 | 8,075 | 1,825 | 0 |
| 30 Sep 21 | 13,543 | 6,996 | 1,569 | 0 |
| 30 Jun 21 | 12,384 | 6,205 | 1,451 | 0 |
| 31 Mar 21 | 9,198 | 4,004 | 1,384 | 0 |
| 31 Dec 20 | 8,497 | 3,513 | 1,346 | 0 |
| 30 Sep 20 | 7,938 | 3,156 | 1,459 | 0 |
| 30 Jun 20 | 7,387 | 2,984 | 1,437 | 0 |
| 31 Mar 20 | 7,013 | 2,279 | 1,383 | 0 |
| 31 Dec 19 | 6,558 | 2,116 | 1,342 | 0 |
| 30 Sep 19 | 6,622 | 2,144 | 1,381 | 0 |
| 30 Jun 19 | 6,542 | 2,069 | 1,446 | 0 |
| 31 Mar 19 | 6,572 | 2,428 | 1,517 | 0 |
| 31 Dec 18 | 5,146 | 2,444 | 1,127 | 0 |
| 30 Sep 18 | 6,365 | 1,798 | 1,475 | 0 |
| 30 Jun 18 | 6,203 | 1,591 | 1,412 | 0 |
| 31 Mar 18 | 6,065 | 1,428 | 1,354 | 0 |
| 31 Dec 17 | 5,872 | 1,199 | 1,320 | 0 |
| 30 Sep 17 | 5,517 | 1,278 | 1,236 | 0 |
| 30 Jun 17 | 5,236 | 1,155 | 1,200 | 0 |
| 31 Mar 17 | 4,979 | 963 | 1,185 | 0 |
| 31 Dec 16 | 4,860 | 896 | 1,178 | 0 |
| 30 Sep 16 | 4,732 | 797 | 1,147 | 0 |
| 30 Jun 16 | 4,649 | 743 | 1,087 | 0 |
| 31 Mar 16 | 4,435 | 741 | 969 | 0 |
| 31 Dec 15 | 4,104 | 636 | 839 | 0 |
| 30 Sep 15 | 3,808 | 571 | 719 | 0 |
| 30 Jun 15 | 3,396 | 444 | 653 | 0 |
| 31 Mar 15 | 3,063 | 346 | 575 | 0 |
| 31 Dec 14 | 2,820 | 338 | 519 | 0 |
| 30 Sep 14 | 2,628 | 345 | 426 | 0 |
| 30 Jun 14 | 2,499 | 403 | 380 | 0 |
| 31 Mar 14 | 2,291 | 394 | 355 | 0 |
| 31 Dec 13 | 2,105 | 414 | 346 | 0 |
Quality Earnings: REGN has high quality earnings.
Growing Profit Margin: REGN's current net profit margins (33.6%) are higher than last year (30.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REGN's earnings have grown by 7.3% per year over the past 5 years.
Accelerating Growth: REGN's earnings growth over the past year (16.6%) exceeds its 5-year average (7.3% per year).
Earnings vs Industry: REGN earnings growth over the past year (16.6%) exceeded the Biotechs industry 16.6%.
Return on Equity
High ROE: REGN's Return on Equity (15.9%) is considered low.